Article
Gastrointestinal stromal tumours: from KIT to succinate dehydrogenase.
Histopathology - 1 Jan 2014
Doyle Leona A, Hornick Jason L
Abstract excerpt
The discovery of activating mutations in the tyrosine kinase receptor genes KIT and PDGFRA has led to the development of effective targeted therapies for gastrointestinal stromal tumours (GISTs). Specific genotypes, in part, predict the response to treatment with tyrosine kinase inhibitors. However, ~10% of GISTs lack such mutations (often referred to as 'wild-type' GISTs). Recent insights into the biology of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
